TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shionogi & Co ( (JP:4507) ) just unveiled an update.
Shionogi & Co., Ltd. announced promising results from its Phase 3 trial of ensitrelvir, an oral antiviral drug, which showed a significant reduction in the risk of developing COVID-19 when used as post-exposure prophylaxis. This development positions ensitrelvir as a potential breakthrough in preventing COVID-19, especially for high-risk individuals, and highlights Shionogi’s commitment to addressing unmet medical needs in infectious disease prevention.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, focusing on the development and distribution of medicines, particularly in the area of infectious diseases. The company is known for its work on antiviral drugs and has been actively involved in creating treatments for COVID-19.
YTD Price Performance: 22.15%
Average Trading Volume: 312
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.59B
See more insights into 4507 stock on TipRanks’ Stock Analysis page.